Voided urine test to diagnose prostate cancer: Preliminary report.

Authors

R B Nerli, Department of Urology, Division of Urologic-Oncology, JN Medical College, KLE Academy of Higher Education and Research, JNMC Campus, Belagavi, Karnataka, India; Urinary Biomarkers Research Centre, KLES Dr. Prabhakar Kore Hospital and M.R.C, Belagavi, Karnataka, India
Shridhar C Ghagane, Department of Urology, Division of Urologic-Oncology, JN Medical College, KLE Academy of Higher Education and Research, JNMC Campus, Belagavi, Karnataka, India; Urinary Biomarkers Research Centre, KLES Dr. Prabhakar Kore Hospital and M.R.C, Belagavi, Karnataka, India
Saziya R Bidi, Urinary Biomarkers Research Centre, KLES Dr. Prabhakar Kore Hospital and M.R.C, Belagavi, Karnataka, India
Mathew L Thakur, Department of Urology, Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States; Department of Urology, Thomas Jefferson University, Philadelphia, Pennsylvania, United StatesFollow
Leonard G Gomella, Department of Urology, Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States; Department of Urology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States; The Sidney Kimmel Cancer Centre, Thomas Jefferson University, Philadelphia, Pennsylvania, United StatesFollow

Document Type

Article

Publication Date

10-2-2021

Comments

This article is the author's final published version in CytoJournal, October 2021, Volume 18.

The published version is available at https://doi.org/10.25259/Cytojournal_76_2020

Copyright © 2021 Cytopathology Foundation Inc, Published by Scientific Scholar

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Abstract

Objectives: Prostate cancer (PCa) is a common malignancy affecting elderly male. At present, PCa is estimated using serum prostate-specific antigen (PSA). Prostate biopsy remains the gold standard to confirm the diagnosis of PCa. In this preliminary study, we have assessed the feasibility of detecting PCa using voided urine by targeting the genomic vasoactive intestinal peptide receptor (VPAC) expressed on malignant PCa cells.

Material and Methods: Patients ≥40 years old, with no lower urinary tract symptoms (LUTS) and serum PSA levels of2.6 ng/ mL formed the study group. Patients were advised to give the first 50 mL of voided urine sample for the detection of malignant markers by targeting the VPAC. The results of histopathological studies were then compared to the results of urine biomarker.

Results: The study revealed absence of malignant markers in 75 patients (control group). In the study group, all the 33 patients with adenocarcinoma were positive for malignant markers in the biomarker study and absence of malignant markers in the 32 patients with benign histology. The results of the biomarker studies and histopathology were consistent with each other.

Conclusion: This preliminary study validates our belief that patients with PCa do shed malignant cells in the urine which can be identified by targeting the VPAC. The investigation is easy and our data appear to be highly encouraging and further serve as a simple, reliable, and a non-invasive tool in the detection of PCa.

Recommended Citation

Nerli, R B; Ghagane, Shridhar C; Bidi, Saziya R; Thakur, Mathew L; and Gomella, Leonard G, "Voided urine test to diagnose prostate cancer: Preliminary report." (2021). Department of Urology Faculty Papers. Paper 67.
https://jdc.jefferson.edu/urologyfp/67

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.

PubMed ID

34754324

Language

English